Biocartis launches CE-marked IVD test for lung cancer


Biocartis Group NV (‘Biocartis’ or the ‘Company’), an innovative molecular diagnostics company (Euronext Brussels: BCART), today announced the CE-marking of the Idylla™ EGFR Mutation Test, as such achieving an important milestone in Biocartis’ lung cancer menu. The test is the only on market fully automated CE-IVD test that detects all relevant EGFR mutations according to international guidelines1. A comparison study2 of the Idylla™ EGFR Mutation Test, of which an abstract was published at the 2017 ASCO Annual Meeting3, compared the test with a commonly used EGFR pyrosequencing-based test4. This study concluded that the Idylla™ EGFR Mutation Test produced the results faster and easier, based on only one slice of tumor tissue5. As such this test has the potential to expand EGFR testing to more pathology laboratories in a reliable and fast manner.

Lung cancer is the most common cancer worldwide, contributing for 13% of all cancer types6 and in total 85% of lung cancers are non-small cell lung cancers (NSCLC)7. The prevalence of EGFR mutations in NSCLC is 10-15% in Western and up to 50% in Asian patients8. Today, EGFR mutation testing is recommended in all patients with advanced NSCLC of a non-squamous subtype9. Current molecular testing of lung cancer samples however is still a very complex process. It can take up to several weeks10 before results are generated, mainly because obtaining high quality tissue samples is difficult. Samples are often small, with a limited amount of available lung tumour tissue, leading to failure of test results in a significant number of cases. Moreover, many laboratories do not have the necessary infrastructure to perform complex molecular tests, resulting in laboratories sending out their samples to other testing facilities, causing long waiting times.


The Idylla™ EGFR Mutation Test, performed on Biocartis’ Idylla™ platform, is designed to improve today’s complex EGFR testing workflows. The test allows the detection of 51 EGFR mutations directly from only one slice of FFPE tissue, in contrast with traditional EGFR testing methods that often require up to six or more tumor slices. The test delivers results in approx. 2.5 hours with less than 2 minutes hands-on time. The clinical performance evaluation comparing the Idylla™ EGFR Mutation Test with a Polymerase Chain Reaction (PCR) based reference method showed an overall agreement of 96%11 for mutations in the EGFR oncogene. A comparison study2, of which an abstract was published at the 2017 ASCO Annual Meeting, compared the EGFR Mutation Test on the Idylla™ platform to a pyrosequencing method commonly used in clinical practice. This study concluded that the Idylla™ EGFR Mutation Test produced the results faster (sample-to-result time was about 180 minutes with about two minutes of hands-on time) than pyrosequencing (sample to result time about 12 hours) and easier.


Paola Valente, Strategic Marketing Director of Biocartis, commented: “Many of our customer-laboratories have been waiting for the CE-IVD marking of our Idylla™ EGFR Mutation Test. EGFR testing on Idylla™ is easier and faster than other solutions available on the market today. As such, the Idylla™ EGFR Mutation Test will allow more wide-spread EGFR testing of lung cancer patients, without the need for specialized laboratory infrastructure.”


The newly launched Idylla™ EGFR Mutation Test is an important addition to Biocartis’ CE-marked IVD test menu, now consisting of five CE-marked IVD tests for melanoma, colorectal and lung cancer. A liquid biopsy version of this test, the Idylla™ ctEGFR Mutation Assay (Research Use Only or RUO), is under development and expected in H2 2017.



More information:
Renate Degrave
Manager Corporate Communications & Investor Relations Biocartis
tel +32 15 631 729
mob +32 471 53 60 64



Interested in a regular update of the Life Sciences and biotech sector in Flanders?